Results 1 to 10 of about 126,534 (277)

Glucagon-like peptide 1 (GLP-1) [PDF]

Molecular Metabolism, 2019
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying ...
T.D. Müller, B. Finan, S.R. Bloom, D. D'Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi, M.H. Tschöp   +24 more
doaj   +11 more sources

Glucagon-Like Peptide-1

JACC: Basic to Translational Science, 2016
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc, Sophie J. Clarke, BSc, David P. Dutka, MD, Stephen P. Hoole, MA, DM   +3 more
doaj   +3 more sources

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration

Scientific Reports, 2023
Accumulating evidence suggests that metabolic demands of the regenerating liver are met via lipid metabolism and critical regulators of this process. As such, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) critically affect hepatic ...
Markus Ammann, Jonas Santol, David Pereyra, Tamara Kalchbrenner, Tanja Wuerger, Johannes Laengle, Rory L. Smoot, Wolfgang Hulla, Friedrich Laengle, Patrick Starlinger   +9 more
doaj   +3 more sources

Equine glucagon-like peptide-1 receptor physiology [PDF]

PeerJ, 2018
Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder, Simon R. Bailey, Kevin J. Dudley, Martin N. Sillence, Melody A. de Laat   +4 more
doaj   +5 more sources

Adult human biliary tree stem cells differentiate to β-pancreatic islet cells by treatment with a recombinant human Pdx1 peptide [PDF]

, 2015
Generation of β-pancreatic cells represents a major goal in research. The aim of this study was to explore a protein-based strategy to induce differentiation of human biliary tree stem cells (hBTSCs) towards β-pancreatic cells.
Alvaro, Domenico, Berloco, Pasquale Bartolomeo, Cardinale, Vincenzo, Carpino, Guido, Casa, Domenico, DE CANIO, Michele, Federici, Giorgio, Gaudio, Eugenio, Maroder, Marella, Nevi, Lorenzo, Panetta, Rocco, Puca, Rosa, Reid, Lola M., Renzi, Anastasia, Scafetta, Gaia, Sicilia, Francesca   +15 more
core   +15 more sources

Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]

Current Opinion in Lipidology, 2016
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects.
Thomas A. Lutz, Elena Osto
openaire   +2 more sources

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

Journal of Diabetes Investigation, 2020
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami, Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Daisuke Yabe, Nobuya Inagaki   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2017
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj   +1 more source